US 11,938,104 B1
Compositions and methods for prevention and treatment of coronavirus and related disorders
Jesus E. Villafranca, San Diego, CA (US); and Charles Richard Kissinger, San Diego, CA (US)
Assigned to ABREXA PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by Abrexa Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Jan. 11, 2022, as Appl. No. 17/573,503.
Claims priority of provisional application 63/135,875, filed on Jan. 11, 2021.
Int. Cl. A61K 31/167 (2006.01); A61K 31/4365 (2006.01); A61K 31/616 (2006.01); A61K 31/7064 (2006.01); A61K 31/727 (2006.01); A61K 38/48 (2006.01); A61P 7/02 (2006.01)
CPC A61K 31/167 (2013.01) [A61K 31/4365 (2013.01); A61K 31/616 (2013.01); A61K 31/7064 (2013.01); A61K 31/727 (2013.01); A61K 38/482 (2013.01); A61P 7/02 (2018.01)] 3 Claims
OG exemplary drawing
 
1. A method of reducing a risk of, inhibiting, reducing, or mitigating coronavirus-induced vascular instability in a subject, comprising administering to the subject a therapeutically effective amount of a compound having the structure of Formula IV:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof.